icone plus
Contact Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TECENTRIQ (atezolizumab).
See also
Décision d'accès précoce
25/11/2022
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
PNH9kU5PKx1wGSXY
Listen
